AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16359825 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition (very light intensity cycle ergometry, n=19)
Number of subjects: 37
Study 12816263 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infiltration at Mayfield skull‐pin sites
Number of subjects: 30
Study 12816263 — intervention group
Group type: COMPARATOR
Intervention: Placebo infiltration at Mayfield skull‐pin sites
Number of subjects: 30
Study 11008326 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tryptophan (500 mg)
Number of subjects: 8
Study 11008326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8763553 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-directed instruction
Number of subjects: 4
Study 8763553 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted instruction
Number of subjects: 4
Study 1673628 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.075 mg once daily)
Number of subjects: 30
Study 1673628 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg twice daily)
Number of subjects: 30
Study 1673628 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 30
Study 1673628 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 and Bromocriptine
Number of subjects: 30
Study 1673628 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502, Bromocriptine, and Normal Controls
Number of subjects: 30
Study 6813805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin for 1 day
Number of subjects: 0
Study 6813805 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin for 1 day
Number of subjects: 0
Study 6813805 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin for 5 days
Number of subjects: 0
Study 31519130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated, Accelerated Radiotherapy (HART) prescribed as 76 Gy in 56 fractions, 10 fractions weekly; no chemotherapy
Number of subjects: 295
Study 31519130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated, Accelerated Radiotherapy (HART)
Number of subjects: 295
Study 28656723 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 18
Study 28656723 — intervention group
Group type: COMPARATOR
Intervention: Conventional autogenous block grafts
Number of subjects: 18
Study 26393991 — intervention group
Group type: EXPERIMENTAL
Intervention: EA During HBOT
Number of subjects: 60
Study 26393991 — intervention group
Group type: COMPARATOR
Intervention: HBOT
Number of subjects: 60
Study 26393991 — intervention group
Group type: COMPARATOR
Intervention: EA
Number of subjects: 60
Study 26393991 — intervention group
Group type: COMPARATOR
Intervention: EA Combined With Pure O₂
Number of subjects: 60
Study 23552462 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma skills training using 2 simulation models replicating melanomas and abnormal or benign nevi.
Number of subjects: 74
Study 21551510 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day
Number of subjects: 232
Study 21551510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 19463517 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 36
Study 19463517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Number of subjects: 36
Study 16710429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PR)
Number of subjects: 253
Study 16710429 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 253
Study 15195061 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin C applied to the intact tympanic membrane
Number of subjects: 15
Study 15195061 — intervention group
Group type: COMPARATOR
Intervention: Saline applied to the intact tympanic membrane (control)
Number of subjects: 15
Study 11490039 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 22
Study 11490039 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 22
Study 11490039 — intervention group
Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 22
Study 9766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care for women with high-risk pregnancies
Number of subjects: 150
Study 9766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational diabetes
Number of subjects: 150
Study 9766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 150
Study 9766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for hospitalizations
Number of subjects: 150
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol 150 mg/day
Number of subjects: 168
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol 300 mg/day
Number of subjects: 168
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol 450 mg/day
Number of subjects: 168
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol 600 mg/day
Number of subjects: 168
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 168
Study 7859799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifibrol (high baseline levels > 30 mg.dl-1)
Number of subjects: 168
Study 7859799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 2702158 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen fleece implanted in osseous defect
Number of subjects: 70
Study 2702158 — intervention group
Group type: COMPARATOR
Intervention: Iodoform gauze packed in osseous defect
Number of subjects: 70
Study 31600432 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD), 12 sessions
Number of subjects: 31
Study 28403937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.2mg.kg‐1.min‐1 for 14h)
Number of subjects: 8
Study 28403937 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 26680421 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT; n = 20)
Number of subjects: 43
Study 26680421 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity Training (LIT; n = 23)
Number of subjects: 43
Study 23414245 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-A (15% NovaMin(®) and NaF)
Number of subjects: 151
Study 23414245 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-B (15% NovaMin(®))
Number of subjects: 151
Study 23414245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 21154218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.23 mg/kg bolus followed by 0.64 mg/kg/h)
Number of subjects: 8
Study 21154218 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 18450360 — intervention group
Group type: EXPERIMENTAL
Intervention: Levovist (galactose-based air-filled microbubbles)
Number of subjects: 138
Study 18450360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonovue (sulphur hexafluoride-filled microbubbles)
Number of subjects: 138
Study 17598307 — intervention group
Group type: EXPERIMENTAL
Intervention: DLF-task group
Number of subjects: 20
Study 17598307 — intervention group
Group type: EXPERIMENTAL
Intervention: DLI-task group
Number of subjects: 20
Study 17598307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 12560955 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal electrical stimulation of common peroneal nerve in bipedal stance
Number of subjects: 20
Study 12560955 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal electrical stimulation of common peroneal nerve in monopedal stance
Number of subjects: 20
Study 10696840 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment for large adenomas and early colorectal cancer
Number of subjects: 0
Study 10696840 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening strategies including endoscopy and fecal occult blood tests
Number of subjects: 0
Study 10696840 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy as a diagnostic tool
Number of subjects: 0
Study 9095879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing
Number of subjects: 100
Study 9095879 — intervention group
Group type: COMPARATOR
Intervention: Opsite IV3000 dressing
Number of subjects: 100
Study 8245326 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (1,681 patients)
Number of subjects: 3187
Study 8245326 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (1,658 patients)
Number of subjects: 3187
Study 3888709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% domoprednate
Number of subjects: 85
Study 3888709 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate
Number of subjects: 85
Study 29609930 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticulture-related activities (HRAs) including floral arranging, planting, and flower pressing
Number of subjects: 20
Study 29609930 — intervention group
Group type: COMPARATOR
Intervention: Control group activities (individual favorite indoor activities)
Number of subjects: 20
Study 29609930 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticulture-related activities (HRAs)
Number of subjects: 20
Study 26771854 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma (Group A: previously operated on and received postoperative radiosurgery; Group B: previously operated on but did not receive postoperative radiosurgery)
Number of subjects: 53
Study 26771854 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma (Group A and B)
Number of subjects: 53
Study 26771854 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for recurrent vestibular schwannoma
Number of subjects: 53
Study 26771854 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C: primarily operated on VS)
Number of subjects: 53
Study 23934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus acidophilus and Bifidobacteria lactis 2 × 10^E CFU/d
Number of subjects: 49
Study 23934538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 49
Study 23214247 — intervention group
Group type: EXPERIMENTAL
Intervention: CCS combined with NBT and YB capsules
Number of subjects: 65
Study 23214247 — intervention group
Group type: COMPARATOR
Intervention: CCS with NBT only
Number of subjects: 65
Study 20164307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 104.9 mg . kg(‐1) . d(‐1)
Number of subjects: 11
Study 20164307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 117.6 mg . kg(‐1) . d(‐1)
Number of subjects: 11
Study 20164307 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded intakes of lysine
Number of subjects: 11
Study 17515572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m2 every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery
Number of subjects: 70
Study 17515572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (docetaxel and carboplatin)
Number of subjects: 70
Study 17515572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 70
Study 16135575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 25 mg
Number of subjects: 100
Study 16135575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14588285 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography in subjects with mild persistent low back pain
Number of subjects: 25
Study 14588285 — intervention group
Group type: COMPARATOR
Intervention: Control group (52 subjects with chronic low back pain illness)
Number of subjects: 25
Study 10458713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment for 6 weeks
Number of subjects: 60
Study 10458713 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 60
Study 7541660 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim)
Number of subjects: 76
Study 7541660 — intervention group
Group type: COMPARATOR
Intervention: Control (no growth factor)
Number of subjects: 76
Study 2218849 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control of risk factors for stroke including hypertension, diabetes, and hyperlipidemia, and antiplatelet aggregant medication)
Number of subjects: 36
Study 2218849 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment plus superficial temporal‐to‐middle cerebral artery bypass
Number of subjects: 36
Study 2218849 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment plus carotid endarterectomy
Number of subjects: 36
Study 810270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhalation
Number of subjects: 8
Study 810270 — intervention group
Group type: COMPARATOR
Intervention: Cold room exposure (3 degrees C)
Number of subjects: 8
Study 31087723 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram treatment for 12 weeks
Number of subjects: 70
Study 31087723 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 70
Study 28871440 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin (C7)
Number of subjects: 32
Study 28871440 — intervention group
Group type: COMPARATOR
Intervention: Trioctanoin (C8)
Number of subjects: 32
Study 26475215 — intervention group
Group type: EXPERIMENTAL
Intervention: Total WBC counts
Number of subjects: 0
Study 26475215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte counts
Number of subjects: 0
Study 26475215 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood CRP, interleukin-6, and leptin
Number of subjects: 0
Study 23982574 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic virtual reality simulation training plus standard robotic orientation
Number of subjects: 18
Study 23982574 — intervention group
Group type: COMPARATOR
Intervention: Standard robotic orientation alone
Number of subjects: 18
Study 22047664 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of hCG
Number of subjects: 167
Study 22047664 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of hCG
Number of subjects: 167
Study 22047664 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU of hCG
Number of subjects: 167
Study 22047664 — intervention group
Group type: COMPARATOR
Intervention: Control (no hCG)
Number of subjects: 167
Study 19095174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions compared in RCTs with negative results
Number of subjects: 0
Study 19095174 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16454830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin, arbekacin inhalation, and oral sulfamethoxazole/trimethoprim (Group C)
Number of subjects: 72
Study 16454830 — intervention group
Group type: COMPARATOR
Intervention: MRSA-positive not eradicated (Group B)
Number of subjects: 72
Study 16454830 — intervention group
Group type: COMPARATOR
Intervention: MRSA-negative (Group A)
Number of subjects: 72
Study 14569279 — intervention group
Group type: EXPERIMENTAL
Intervention: First Step Program (FSP)
Number of subjects: 47
Study 14569279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 10772515 — intervention group
Group type: EXPERIMENTAL
Intervention: 7F Tail stent
Number of subjects: 60
Study 10772515 — intervention group
Group type: COMPARATOR
Intervention: 7F double-pigtail stent
Number of subjects: 60
Study 9494767 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 4673
Study 9494767 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 4673
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala 20 g orally
Number of subjects: 12
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala 40 g orally
Number of subjects: 12
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg orally
Number of subjects: 12
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 5.0 mg orally
Number of subjects: 12
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.25 mg
Number of subjects: 12
Study 8375242 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 0.4 mg
Number of subjects: 12
Study 8375242 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic subjects (placebo)
Number of subjects: 12
Study 2437789 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 70
Study 2437789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (500 mg)
Number of subjects: 0
Study 28857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 mg)
Number of subjects: 0
Study 28857147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline + Ambrisentan
Number of subjects: 0
Study 28857147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26892848 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 26892848 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study 25074072 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NGM (ethinyl estradiol and norgestimate)
Number of subjects: 201
Study 25074072 — intervention group
Group type: COMPARATOR
Intervention: EE/DSG (ethinyl estradiol and desogestrel)
Number of subjects: 201
Study 25074072 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NGM
Number of subjects: 201
Study 25074072 — intervention group
Group type: COMPARATOR
Intervention: EE/DSG
Number of subjects: 201
Study 22705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased schooling (randomized intervention)
Number of subjects: 0
Study 20420792 — intervention group
Group type: COMPARATOR
Intervention: Dorixina Forte (reference product)
Number of subjects: 26
Study 20420792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestodol (test formulation)
Number of subjects: 26
Study 17651517 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d
Number of subjects: 199
Study 17651517 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d
Number of subjects: 199
Study 17651517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 15961582 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero exposure to background levels of PCBs (low exposure category <1.25 microg of PCB/liter of serum)
Number of subjects: 894
Study 15961582 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero exposure to background levels of PCBs (high exposure category >=5 microg of PCB/liter of serum)
Number of subjects: 894
Study 15961582 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in PCB level (microg/liter)
Number of subjects: 894
Study 12756570 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training at 180 degrees s(‐1) (3.14 rad s(‐1))
Number of subjects: 26
Study 12756570 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training at 30 degrees s(‐1) (0.52 rad s(‐1))
Number of subjects: 26
Study 12756570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 26
Study 10332784 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional evaluation by machine
Number of subjects: 0
Study 10332784 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 0
Study 8945796 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 239
Study 8945796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 1769635 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (2 x 75 micrograms)
Number of subjects: 10
Study 1769635 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2 x 20 mg retard)
Number of subjects: 10
Study 1769635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Clonidine and Nifedipine (C/N)
Number of subjects: 10
Study 7038497 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24
Study 7038497 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 24
Study 7038497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31479003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost for 5 min
Number of subjects: 0
Study 31479003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28794410 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, and oral hygiene instruction
Number of subjects: 0
Study 28794410 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP)
Number of subjects: 0
Study 28794410 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene care programme (COHCP)
Number of subjects: 0
Study 26470711 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 24
Study 26470711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate
Number of subjects: 24
Study 26470711 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium
Number of subjects: 24
Study 23126237 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (160/4.5 μg 1 inhalation twice daily plus as-needed budesonide/formoterol 160/4.5 μg)
Number of subjects: 2091
Study 23126237 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol plus terbutaline (160/4.5 μg 1 inhalation twice daily plus as-needed terbutaline 0.4 mg)
Number of subjects: 2091
Study 21816079 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation training (16 sessions lasting 8 weeks)
Number of subjects: 61
Study 21816079 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 61